Form 4: Twist Bioscience CFO Adam Laponis Sells Shares to Cover Tax Obligations

Adam Laponis, CFO of Twist Bioscience, sold 2,542 shares of common stock on April 9, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 9, 2025, Adam Laponis, the Chief Financial Officer of Twist Bioscience Corp, sold 2,542 shares of the company's common stock.
• The sale was executed at a price of $34.9674 per share.
• The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Laponis directly owns 106,954 shares of Twist Bioscience Corp.
• The sale was mandated by Twist Bioscience's equity incentive plan, requiring a 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction reflects a standard procedure for managing equity compensation and does not necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• Similar transactions are routinely observed across the biotechnology industry among executives at companies like Illumina (ILMN), Pacific Biosciences (PACB), and Ginkgo Bioworks (DNA).
• These companies' executives often sell shares acquired through equity compensation to cover tax liabilities, aligning with standard practices in the sector.
• The scale of the transaction is relatively small compared to the overall holdings of the executive, which is typical for such tax-related sales.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
• Employees are not directly impacted by this transaction.

Key Dates

Keywords

Twist Bioscience, Adam Laponis, CFO, stock sale, Form 4, tax withholding, restricted stock units, TWST